Rhythm Pharmaceuticals (RYTM) said Thursday the first patients have been dosed with setmelanotide in a phase 2 trial to treat genetic obesity and in a...
Rhythm Pharmaceuticals (RYTM) has an average rating of outperform and price targets ranging from $14 to $50, according to analysts polled by Capital IQ....
Rhythm Pharmaceuticals (RYTM) said Monday it agreed to grant RareStone an exclusive license to develop and commercialize Imcivree as a potential treatment...
Rhythm Pharmaceuticals (RYTM) has an average outperform rating and a price target range of $14 to $50, according to analysts polled by Capital IQ. (MT...
| Address | 222 Berkeley Street Boston, Massachusetts 02116 |
| Phone | +1.857.264.4280 |
| Number of Employees | 54 |
| Recent SEC Filing | 12/10/2021 SC 13G/A |
| Chairman, President & Chief Executive Officer | David P. Meeker |
| Chief Financial Officer & Treasurer | Hunter C. Smith |
| Head of Research | Alastair Garfield |
| Vice President-Medical Affairs | Brieana Buckley |
| Price Open | $8.49 |
| Previous Close | $8.61 |
| 52 Week Range | $8.33 - 43.26 |
| Market Capitalization | $453.9 M |
| Shares Outstanding | 50.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/07/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.29 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -4,610.55% |
| Return on Equity | -20.19% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
